National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Letermovir (Prevymis®)

Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).

NCPE Assessment Process Complete
Rapid review commissioned 12/03/2018
Rapid review completed 10/05/2018
Rapid Review outcome A Full pharmacoeconomic assessment is recommended
HTA commissioned by the HSE 29/05/2018
Pre-submission consultation with Applicant 09/07/2018
Submission received from Applicant 02/04/2019
Preliminary review sent to Applicant 29/08/2019
NCPE assessment re-commenced 27/09/2019
Preliminary review # 2 sent to Applicant 25/11/2019
NCPE assessment re-commenced 05/12/2019
Factual accuracy check sent to Applicant 24/04/2020
NCPE assessment re-commenced 01/05/2020
NCPE assessment complete 19/05/2020
NCPE assessment outcome The NCPE recommends that letermovir be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.